II. Definitions
- Gabapentinoid
- GABA derivatives that inhibit voltage-gated Calcium channels (at the a2d Subunit)
- Gabapentinoid examples include Gabapentin and Pregabalin
III. Indications
- Neuropathic pain (Peripheral Nerve syndromes)
- Multiple Sclerosis
- Parkinson's Disease
- Fibromyalgia
-
Restless Legs Syndrome
- Effective in idiopathic RLS
- Effective in RLS among Hemodialysis patients
-
Epilepsy
- Partial Seizures (adjunctive agent, FDA approved)
-
Generalized Tonic Clonic Seizures (rarely used)
- Low potency as antiepileptic drug
- May worsen idiopathic Generalized Seizures
- Bipolar Disorder
- Anxiety Disorder
-
Alcohol Dependence
- Doses of 600 mg orally three times daily appear to decrease Alcohol cravings
- Opioid Dependence
IV. Efficacy
- Chronic Pain (NNT 4.3)
- Diabetic Neuropathy (NNT 2.9)
- Postherpetic Neuralgia (NNT 3.9)
V. Safety
- Pregnancy Category C
- Excreted in Breast Milk
- Safe in liver disease (not hepatically metabolized)
- Reduce dose in renal Impairment
VI. Mechanism
- GABA Amino Acid derivative (does not bind GABA-A or GABA-B Receptors)
- Binds presynaptic alpha2-delta1 subunit of Central Nervous System voltage-gated Calcium channels
- Decreases excitatory Neurotransmitter release and activity
VII. Metabolism
-
Bioavailability varies by dose
- Larger doses have lower Bioavailability
- Divided doses result in better Bioavailability
- Half-Life: 5 to 7 hours
- Therapeutic Dose: 4-8 ug/ml
- Primarily renal excretion in its original form (not metabolized)
VIII. Adverse Effects: Standard Dosing
- Most common
- Other adverse effects
- Weight gain
- Peripheral Edema
- Nausea
- Fatigue
- Nystagmus
- Withdrawal symptoms
- Avoid stopping abruptly from higher doses (taper off)
- Risk of Abuse
- Gabapentin and Pregabalin (Lyrica) are abused by patients on Opiates to potentiate CNS Opiate effects
- More than one quarter of Opiate patients have abused Gabapentin
- Pregabalin (Lyrica) is more potent with faster onset and has higher abuse potential than Gabapentin
- Lyrica is categorized as DEA Controlled Substance Class V (and Gabapentin in several states)
- Smith (2012) Br J Gen Pract 62(601):406-7 +PMID:22867659 [PubMed]
- Cardiovascular Events
- Single retrospective EHR chart review associated Gabapentin and Pregabalin with cardiovascular events
- Higher quality confirmatory studies are needed
- Pan (2022) Cardiovasc Diabetol 21(1):170 +PMID: 36050764 [PubMed]
IX. Adverse Effects: Overdose
- Acute Overdose: Sedative-Hypnotic effects
- Sleepy or lethargic
- Normal Vital Signs
- Chronic toxicity (especially with Renal Insufficiency)
- Progressive weakness
- Fatigue
- Altered Level of Consciousness
- Falls
X. Preparations: Newer related agents
-
Pregabalin (Lyrica)
- Indicated in Neuropathy
- More potent than Gabapentin, and possibly less Fatigue
- Gabapentin extended release (Gralise)
- Taken once daily in doses 300 to 1800 mg for Postherpetic Neuralgia
- Avoid in patients with Creatinine Clearance <30 ml/min or on Hemodialysis
- Gabapentin extended release (Horizant)
- Taken 600 mg orally daily (restless legs) to twice daily (Postherpetic Neuralgia)
XI. Dosing: Neuropathy in Adults
- See metabolism above for maximum dosing in renal Impairment
- Starting Dose
- Start Gabapentin at 300 mg orally at bedtime
- Advance to 300 mg orally three times daily (over 4-7 days)
- Plan to ultimately increase to 600 mg three times daily
- Patients tolerate starting 300 three times daily without titrating
- Fisher (2001) Neurology 56(6):743-8 [PubMed]
- Average Dose: 600 mg orally three times daily
- Maximum Dose: 1200 mg orally three times daily
- No increase in Bioavailability above 1200 mg orally three times daily
- Minimal pain benefit above 1800 mg/day in most conditions studied
- Stopping (similar to Pregabalin)
- Taper off agent over 1 week or more
- Avoid stopping abruptly due to withdrawal symptoms
XII. Dosing: Neuropathy in Children
- See metabolism above for maximum dosing in renal Impairment
- Not FDA approved (off label use)
- Day 1: Give 5 mg/kg orally at bedtime
- Day 2: Give 5 mg/kg orally twice daily
- Day 3: Give 5 mg/kg orally three times daily
- Titrate to Target dose: 8 to 35 mg/kg/day divided three times daily
XIII. Dosing: Partial Seizure Prophylaxis
- See metabolism above for maximum dosing in renal Impairment
- Child (age 3-12 years old)
- Start 10-15 mg/kg/day divided three times daily
- Titrate to Target dose: 25 to 35 mg/kg/day (40 mg/kg/day if age 3 to 4 years old) divided three times daily
- Maximum: 40 mg/kg/day (up to 3600 mg/day)
- Adult (and children age >12 years old)
- Start 300 mg orally three times daily
- Typical dose 300 to 600 mg orally three times daily
- Maximum: 1800 to 2400 mg are well tolerated (3600 mg/day is absolute maximum)
XIV. Dosing: Posthepetic Neuralgia
- See Postherpetic Neuralgia
- See metabolism above for maximum dosing in renal Impairment
- Gabapentin
- Day 1: 300 mg orally once
- Day 2: 300 mg orally twice daily
- Day 3: 300 mg orally three times daily
- Titrate as needed for reduction in pain (up to 1800 mg/day)
- Long Acting Agents
- Gralise once daily in doses titrated up from 300 to 1800 mg over 2 weeks for Postherpetic Neuralgia
- Horizant started at 600 mg orally daily for 3 days, then 600 mg orally twice daily
XV. Dosing: Miscellaneous Other Use
- See metabolism above for maximum dosing in renal Impairment
- Mostly off label (non-FDA approved usage)
-
Restless Leg Syndrome
- Gabapentin 300 mg orally 2 hours before bed
- Horizant 600 mg orally at dinner
-
Alcohol Dependence
- Target dose 600 mg orally three times daily (start lower and titrate to dose)
-
Migraine Prophylaxis
- Start 300 mg orally at bedtime
- Titrate to 1800 to 2400 mg/day divided three times daily
-
Hot Flushes
- Take 300 mg orally three times daily
XVI. Drug Interactions
- No significant Drug Interactions
- However, Renal Insufficiency results in drug accumulation
XVII. Resources
- Gabapentin (DailyMed)
- Gralise (DailyMed)
- Horizant (DailyMed)
XVIII. References
- (2016) Crit Dec Emerg Med 30(9):24
- (2022) Presc Lett, Resource #361206, Antiseizure Medications
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
- LoVecchio (2022) Crit Dec Emerg Med 36(4): 36
- Lapoint (2021) EM:Rap 21(6): 16-7
- Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 56-7
- Wiffen (2005) Cochrane Database Syst Rev (3):CD005452 +PMID: 16034978 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
gabapentin (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
GABAPENTIN 100 MG CAPSULE | Generic | $0.03 each |
GABAPENTIN 250 MG/5 ML SOLN | Generic | $0.09 per ml |
GABAPENTIN 300 MG CAPSULE | Generic | $0.04 each |
GABAPENTIN 400 MG CAPSULE | Generic | $0.06 each |
GABAPENTIN 600 MG TABLET | Generic | $0.10 each |
GABAPENTIN 800 MG TABLET | Generic | $0.13 each |
neurontin (on 7/19/2023 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
NEURONTIN 300 MG CAPSULE | Generic | $0.04 each |
NEURONTIN 600 MG TABLET | Generic | $0.10 each |
horizant (on 1/1/2023 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
HORIZANT ER 300 MG TABLET | $14.98 each | |
HORIZANT ER 600 MG TABLET | $14.94 each | |
gralise (on 5/1/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
GRALISE ER 300 MG TABLET | $9.76 each | |
GRALISE ER 600 MG TABLET | $9.79 each |